Role of Oral Probiotics in Vaginal Candidiasis

Efficacy of oral Probiotic therapy for women with Vulvovaginal Candidiasis: A randomized controlled study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070646

Enrollment

Registered

2024-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B373- Candidiasis of vulva and vagina

Interventions

Intervention1: Oral Probiotics and standard antifungal therapy: oral probiotic (Group 1) (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) and Tab Flu

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Adult premenopausal women (age 18-50 years), Symptomatic vulvovaginal candidiasis Exclusion Criteria: Vaginal infections different from VVC, Women treated with other probiotics, pregnancy, lactation, menstruation and a subject’s unwillingness to provide informed consent to participate in the trial. History of systemic organic diseases or psychiatric diseases; Other pathologies (immunodeficiency, diabetes, oestrogen-dependent tumours). Long-term use of contraceptives or immunosuppressants; Use of douching, Anaphylactic constitution or allergic to known ingredients of research drugs.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Vaginal infections different from VVC, Women treated with other probiotics, pregnancy, lactation, menstruation and a subject’s unwillingness to provide informed consent to participate in the trial. History of systemic organic diseases or psychiatric diseases; Other pathologies (immunodeficiency, diabetes, oestrogen-dependent tumours). Long-term use of contraceptives or immunosuppressants; Use of douching, Anaphylactic constitution or allergic to known ingredients of research drugs.

Design outcomes

Primary

Measure	Time frame
to evaluate the efficacy of a multispecies oral probiotic formulation Lactobacillus mixture in combination with bifidobacterium bifidum (capsule combinorm, Abbott Pharma India) given orally as an adjuvant to oral standard antimicrobial therapy in women with symptomatic vulvovaginal candidiasisTimepoint: at 2 months after initiating the therapy, if symptoms persists every 2 months until 6 months	—

Secondary

Measure	Time frame
evaluate the recurrence rate in the study population for 6 monthsTimepoint: 6 months after initiating therapy	—

Countries

India

Contacts

Public ContactDr J Aparna

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

draparnaj@gmail.com8106732587

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026